glp-1 drugs and breast cancer cancer: use may substantially lower risk New study links GLP-1 drugs
Description
Besides animal trials, there are clinical data that support the neuroprotective properties of GLP-1 RAs
Another GLP-1 analog, liraglutide (Saxenda), was FDA-approved for weight loss in 2014
They succeeded in identifying miR-7 and validated its particular interaction with ARR1
like in preclinical research, this effect is glucose dependent, occurring only in hypoglycemia [72, 77]
